Page last updated: 2024-12-06

2-acrylamido-2-methylpropanesulfonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Acrylamido-2-methylpropanesulfonate (AMPS) is a versatile monomer used in the synthesis of various polymers. It is a white, crystalline solid with a melting point of 130-135 °C. AMPS is typically synthesized via the reaction of acrylamide with 2-methylpropene-1-sulfonic acid. Its primary applications lie in the production of superabsorbent polymers, which are used in diapers, sanitary napkins, and other absorbent materials. AMPS also finds use in the preparation of water-soluble polymers and flocculants, which are employed in water treatment and wastewater treatment. The unique properties of AMPS, such as its water solubility and ability to form strong hydrogen bonds, make it a valuable building block for various polymeric materials. AMPS-based polymers are also studied for their potential applications in biomedical fields, including controlled drug delivery and tissue engineering. Research on AMPS focuses on developing new and improved polymers with tailored properties for specific applications. '

2-acrylamido-2-methylpropanesulfonate: for detection of alkaline phosphatase; RN given refers to parent cpd; do not confuse with AMPS cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65360
CHEMBL ID1907040
CHEBI ID166476
SCHEMBL ID19490
MeSH IDM0157933

Synonyms (65)

Synonym
2-methyl-2-(prop-2-enoylamino)propane-1-sulonic acid
CHEBI:166476
2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid
1-propanesulfonic acid, 2-methyl-2-[(1-oxo-2-propenyl)amino]-
einecs 239-268-0
1-propanesulfonic acid, 2-methyl-2-((1-oxo-2-propenyl)amino)-
2-acrylamido-2-methylpropanesulfonate
1-propanesulfonic acid, 2-acrylamido-2-methyl-
2-acrylamido-2-methylpropanesulfonic acid (amps)
2-acrylamido-2-methylpropanesulphonic acid
inchi=1/c7h13no4s/c1-4-6(9)8-7(2,3)5-13(10,11)12/h4h,1,5h2,2-3h3,(h,8,9)(h,10,11,12
2-acrylamido-2-methyl-1-propanesulfonic acid, 99%
NCGC00163969-01
15214-89-8
2-(acryloylamino)-2-methylpropane-1-sulfonic acid
A0926
2-acrylamido-2-methylpropanesulfonic acid
2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid
27119-07-9
NCGC00163969-02
cas-15214-89-8
dtxsid5027770 ,
tox21_303523
NCGC00257492-01
2-acrylamido-2-methyl-1-propanesulfonic acid
dtxcid207770
tox21_201781
NCGC00259330-01
2-acrylamide-2-methylpropanesulfonic acid
1-propanesulfonic acid, 2-methyl-2-((1-oxo-2-propen-1-yl)amino)-
490hqe5ki5 ,
unii-490hqe5ki5
ec 239-268-0
2-acrylamido-2-methylpropane sulfonic acid
2-acryloylamido-2-methylpropanesulfonic acid monomer
FT-0610988
AKOS015898709
tert-butylacrylamidosulfonic acid
2-acrylamido-2-methylpropylsulfonic acid
atbs
acryloyldimethyltaurine
2-acrylamido-2,2-dimethylethanesulfonic acid
lubrizol amps
tbas-q
acrylamidomethylpropanesulfonic acid
acrylamide tert-butylsulfonic acid
2-acrylamido-2-methylpropionesulfonate
2-acrylamido-2-methylpropane-1-sulfonic acid
SCHEMBL19490
2-acrylamido-2-methyl propyl sulfonic acid
2-acrylamido-2-methyl-propane sulfonic acid
J-200043
CHEMBL1907040
2-acryloylamido-2-methylpropanesulfonic acid
2-(acryloylamino)-2-methyl-1-propanesulfonic acid #
2-methyl-2-(prop-2-enamido)propane-1-sulfonic acid
mfcd00007522
82989-71-7
2-acrylamido-2-methyl propanesulfonic acid
2-acrylamido-2-methyl-1-propanesulfonic acid, 8ci
5165-97-9 (mono-hydrochloride salt)
E76045
Q209301
2-acrylamido-2-methyl-1-propanesulfonicacid
CS-W015266

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" After 24h exposure, Acticoat™ and Flamazine™ cream were toxic to all tested cell lines."( Cytotoxicity testing of silver-containing burn treatments using primary and immortal skin cells.
Boonkaew, B; Cuttle, L; Kempf, M; Kimble, R, 2014
)
0.4
" These pH-sensitive hydrogels appear to provide an ideal basis as a safe carrier for oral drug delivery."( Facile Synthesis of Chitosan Based-(AMPS-co-AA) Semi-IPNs as a Potential Drug Carrier: Enzymatic Degradation, Cytotoxicity, and Preliminary Safety Evaluation.
Khan, SA; Mannan, A; Murtaza, G; Rashid, H; Shah, A; Sohail, M; Ullah, K, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The results indicated that the dose-response (R2) of AMPS/Bis had a linear trend over a wide dose range."( Characteristics of a novel polymer gel dosimeter formula for MRI scanning: Dosimetry, toxicity and temporal stability of response.
Abtahi, SM, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organosulfonic acidAn organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency38.57080.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency17.31810.000221.22318,912.5098AID1259243; AID1259247; AID1259381
progesterone receptorHomo sapiens (human)Potency15.35480.000417.946075.1148AID1346784; AID1347036
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency61.64480.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency47.14600.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency1.19370.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency36.85050.000229.305416,493.5996AID1259248; AID743078
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency5.37670.001019.414170.9645AID743094
activating transcription factor 6Homo sapiens (human)Potency13.50560.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency13.39370.000323.4451159.6830AID743065
heat shock protein beta-1Homo sapiens (human)Potency38.40670.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.30)18.7374
1990's4 (5.19)18.2507
2000's23 (29.87)29.6817
2010's40 (51.95)24.3611
2020's9 (11.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.74 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index42.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (3.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (96.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]